ABSTRACT Inhaled adenosine 5'-monophosphate (AMP) causes bronchoconstriction in atopic asthma, probably after in vivo conversion to adenosine. It has been suggested that adenosine potentiates preformed mediator release from mast cells on the mucosal surface of the airways by interacting with specific purinoceptors, without affecting the release of newly generated mediators. The airway response of nine non-atopic subjects with "intrinsic" asthma to inhaled AMP and the influence of the oral, selective H, histamine receptor antagonist terfenadine on this response was investigated. The geometric mean provocation concentrations of histamine and AMP required to produce a 20% fall in FEVy (PC20) were 1-82 and 13 mmol/l. In subsequent placebo controlled time course studies the FEV, response to a single inhalation of the PC20 histamine was ablated after pretreatment with oral terfenadine 180 mg. This dose of terfenadine caused an 80% inhibition of the bronchoconstrictor response to the PC20 AMP when measured as the area under the time courseresponse curve and compared with the response to PC20 AMP preceded by placebo. Terfenadine 600 mg failed to increase protection against AMP further, but both doses of terfenadine delayed the time at which the mean maximum fall in FEV, after AMP was achieved. Terfenadine 180 mg had no effect on methacholine induced bronchoconstriction in the same subjects. These data suggest that inhaled AMP may potentiate the release ofpreformed mediators from preactivated mast cells in the bronchial mucosa of patients with intrinsic asthma.
Introduction
Adenosine is a naturally occurring purine nucleoside formed from the cleavage of adenosine 5'-monophosphate (AMP) by 5'-nucleotidase.' Its physiological effects are due to stimulation of cell surface purinoceptors associated with adenylate cyclase, to cause either a decrease (A,) or an increase (A2) in intracellular levels of cyclic 3'5'-AMP.2 When inhaled by atopic subjects with asthma adenosine causes concentration related bronchoconstnction, which reaches maximum 3-5 minutes after challenge and gradually subsides over 30-60 minutes. 3 We have recently reported that the adenosine nucleotide AMP also provokes bronchoconstriction in subjects with allergic asthma, probably after in vivo conversion to adenosine.' The response of asthmatic airways to adenosine is selectively antagonised by the competitive adenosine receptor antagonist theophylline,5 6 and potentiated by the adenosine uptake inhibitor dipyridamole,7 suggesting that it is likely to be occurring through stimulation of specific cell surface purinoceptors.
Recent work suggests that the bronchoconstrictor effect of adenosine depends on the release of spasmogenic mediators from activated bronchial mast cells."'0 Thus adenosine and synthetic analogues with some specificity for A2 purinoceptors potentiate mediator release from preactivated rodent" and human8 mast cells, although this effect appears to be restricted to the release of preformed and not newly generated mediators." 940 contract airway smooth muscle. In subjects with atopic asthma the potent and selective H, histamine receptor antagonists terfenadine and astemizole almost completely inhibit the bronchoconstrictor response to inhaled AMP, while reducing the immediate allergen induced response by only 50%."2 Thus in asthma associated with atopy the airways response to AMP probably results from the augmentation of histamine release from activated mast cells on the surface of the bronchial mucosa.
In 1947 Rackemann introduced the term intrinsic asthma to describe asthmatic patients in whom a causative external allergen could not be implicated. ' USA) , and methacholine (Sigma, Poole, Dorset) were made up in 0 9% sodium chloride to produce a range of doubling concentrations of 0-03-8 mg/ml (0 1-26 mmol/l), 0-04-100mg/ml (1 11-287-9 mmol/l), and 0-03-16 mg/ml (0-16-81-74 mmol/l). The solutions were administ_red as aerosols generated from a starting volume of 3 ml in a disposable Inspiron mini nebuliser (CR Bard International, Sunderland) driven by compressed air at 81/min. -' In these conditions the nebuliser generates an aerosol with a mass median particle diameter of 4-7 Um.'4 Subjects inhaled the aerosolised solutions in five breaths from end tidal volume to full inspiratory capacity via a mouthpiece.'5
STUDY DESIGN
The study was divided into four phases. On day 1, after 15 minutes' rest, three baseline measurements of FEV, were made at three minute intervals. The subjects then inhaled nebulised 0 9% sodium chloride and the FEV, was measured at 1 and 3 minutes, the higher value being recorded. Provided that the FEV, did not fall by more than 10% of the baseline value, a histamine concentration-response study was carried out. After administration of each histamine concentration FEV, was measured at 1 and 
Study 2
Patients attended the laboratory at the same time of day on four occasions, at least 48 hours apart, to undertake time course studies with inhaled histamine and AMP. These were carried out three hours after they had received oral terfenadine 180 mg or matched placebo, randomised separately for each of the two agonists and administered double blind. On each occasion three baseline measurements of FEV, were made at three minute intervals after 15 minutes' rest. Nebulised 0 9% sodium chloride was then administered and repeat FEV, measurements were made at 1 and 3 minutes. If the FEV, did not fall by more than 10% of the baseline value, the previously determined PC2,, histamine or AMP was administered and measurements of FEV, were recorded at regular intervals up to 45 minutes after the challenge. On the two occasions when inhaled histamine was given after oral placebo and terfenadine, a concentration-response study was performed with increasing doubling concentrations of histamine acid phosphate administered by skinprick, the doses ranging from 4 to 128 mg/ ml (13-416 mmol/l). The total weal circumference at 10 minutes with each concentration of histamine was measured by computer assisted planimetry and integrated to obtain weal area.'6 Study 3
The PC20 AMP was administered three hours after subjects had received a higher dose of terfenadine (600 mg) and the changes in FEV, were again followed for 45 minutes as described above. Study 4 Patients attended the laboratory on two further occasions at the same time of day one week apart, to perform a concentration-response study with methacholine, three hours after they had received oral terfenadine 180 mg or matched placebo, randomised and administered double blind.
DATA ANALYSIS
Values are means with standard errors in parentheses unless otherwise stated and p < 0 05 is accepted as significant. Baseline FEV, values after treatment with terfenadine were compared with those after placebo by means of Student's t test for paired data. FEV, at each agonist concentration and time interval was expressed as a percentage of the postsaline value. Since postsaline FEV, values after terfenadine were significantly higher than those after placebo, the agonist constrictor response was expressed as a percentage ofthe postdrug baseline.'7 The slopes of the histamine and AMP concentration-response curves were determined by least squares linear regression analysis and compared by Student's t test to determine whether the curves departed significantly from parallel. In the time course studies the following three indices were selected to characterise the percentage fall in FEV,-time curves: maximum fall in FEV,, rate of fall in FEV, to maximum, and the overall bronchoconstrictor response determined by integrating the area under the curve (AUC) by trapezoid integration. The inhibition of bronchoconstriction achieved by terfenadine was determined by subtracting the area of the FEV,-time course curve after active treatment from that after placebo, and expressing the result as a percentage of the placebo response. The measurements obtained from the time course study were compared by two factor analysis of variance and the Newman-Keuls procedure. The total skin weal areas with histamine for each concentration on terfenadine and on placebo days were compared by Student's t test for paired data. The concentration-response curves with methacholine on the different treatment days, expressed as the PC,, values, were compared by means of Student's t test for paired data.
Results
There were no significant differences in baseline or postsaline FEV, values on any of the study days. Study I The concentration of inhaled histamine required to produce a 20% fall in FEV, from the postsaline baseline (PC20 histamine) ranged from 0-2 to 1.8 mg/ml (0 7-6-0 mmol/l), with a geometric mean of 0 6 mg/ml Administration of the PC20 histamine after placebo caused a rapid fall in FEVY in all subjects reaching a mean maximum of 69-7% ( (fig lb) . The mean time taken to achieve the maximum fall in FEV, with AMP increased from (1 8) minutes after placebo to 9-8 (3 7) minutes after terfenadine 180 mg and 16-6 (3 8) minutes after terfenadine 600 mg). The greater bronchoconstriction observed with the higher dose ofthe antihistamine was due to five subjects in whom terfenadine 600 mg produced only 27-4% (17-4%) inhibition of the AUC, compared with 102-3% (23%) inhibition in the remaining four subjects. Study 4 There was no shift in the methacholine concentrationresponse curves after terfenadine 180 mg (p = 0 5).
PC20 methacholine values ranged from 0 1 to 2-9 mg/ ml (0-3-14-7 mmol/l) after placebo with a geometric mean of 0 4 mg/ml (2-1 mmol/l) and from 0 1-3 0 mg/ ml (0-5-15-3 mmol/l) after terfenadine 180 mg, with a geometric mean value of0 4 mg/ml (2.1 mmol/l) (table 4). This study shows that AMP administered by inhalation to patients with intrinsic (non-atopic) asthma causes bronchoconstriction with a time course similar to that observed with inhaled adenosine in subjects with atopic asthma. 3 We have further shown that, in intrinsic asthma, bronchoconstriction provoked by AMP is inhibited to a major degree by the histamine HI receptor anatagonist terfenadine. The inhibitory effect ofthis selective histamine H, receptor antagonist suggests that release of histamine from activated mast cells in the bronchi has a central role in producing the constrictor airway effects ofAMP and, by implication, adenosine, as previously suggested in atopic asthma.'2 By constructing cumulative concentration-response curves for AMP and histamine and showing that these did not depart significantly from parallel, we were able to define the position of the curves as PC20 values and use these to derive an index of relative potency for the two bronchoconstrictor agonists. In the patients studied AMP was 8-4 times less potent than histamine, on a molar basis, in causing bronchoconstriction, compared with a fourfold difference in potency when the same comparison was made between these two agonists in a group of atopic asthmatic subjects.6 In a previous study no difference in responsiveness to adenosine between atopic and non-atopic asthmatic subjects was found. '8 In this group of non-atopic asthmatic subjects terfenadine 180 mg produced a significant degree of bronchodilatation, similar to that seen in atopic asthma;'9 but it failed to protect the airways against the bronchoconstrictor effect of methacholine. This suggests that in both forms of the disease the airways are under some degree of histamine tone.
After terfenadine 180 mg the bronchoconstrictor response to inhaled AMP was greatly attenuated. The same dose of terfenadine completely inhibited both the bronchoconstrictor response to a dose of inhaled histamine sufficient to cause a mean maximum fall in FEV, to 69 7% of baseline, and the skin weal response to histamine 128 mg/ml (416 mmol/l-figure 2). The specificity of this dose of terfenadine in producing H, histamine receptor blockade is supported in these non-atopic subjects by its failure to protect against bronchoconstriction induced by methacholine. These findings are in agreement with those of two previous studies, which showed a 35 fold protection of the airways against the bronchoconstrictor action of inhaled histamine but no protection against methacholine.'920 We propose therefore that the attenuation ofAMP provoked bronchoconstriction by terfenadine is due to its action as an antagonist of H, histamine receptors and argue for a central role of histamine release in the airways response to this inhaled purine Phillips, Rafferty, Beasley, Holgate derivative in individuals with non-atopic asthma. These results are in agreement with those of a previous study, in which terfenadine and chemically unrelated and potent H, histamine receptor antagonist, astemizole, inhibited the bronchoconstrictor response to AMP in subjects with atopic asthma;'2 but they would appear to contradict the findings of another study, which showed no significant increase in plasma concentrations ofhistamine or neutrophil chemotactic factor after AMP challenge.'0 These latter findings may have been due to lack of sensitivity of the histamine assay or to the selection of subjects with such a high degree of non-specific bronchial reactivity that very little histamine release would be needed before bronchoconstriction occurred.
Histamine is the only known preformed spasmogenic mediator present in the secretory granules of human lung mast cells, so the inhibitory effect of histamine H, receptor antagonists on the airway response to AMP indicates that this nucleotide (and by implication adenosine) causes bronchoconstriction by potentiating ongoing mediator release from activated mast cells in the bronchial mucosa. In atopic asthma the number of mast cells recovered by bronchoalveolar lavage is increased, and their spontaneous release of histamine is greater than from mast cells recovered from normal lung.2' The ability of AMP to provoke an antihistamine sensitive bronchoconstriction in intrinsic asthma suggests that these cells are already activated in the airways-although, as previously discussed, the level ofmast cell activation in the two disease forms may differ. Recently Marquardt et al have reported that adenosine and related synthetic analogues potentiate degranulation of murine interleukin-3 dependent, bone marrow derived mast cells when stimulated for mediator release with the calcium ionophore A23187 or antigen," but do not affect the release of newly generated mediators. Some support for a similar mechanism operating for human lung mast cells is provided by the observation that adenosine and its non-hydrolysable analogues have no effect as secretagogues oflung mast cells per se, but are able to potentiate ongoing IgE dependent histamine release.8
In the patients with intrinsic asthma we studied, terfenadine 180 mg inhibited the airways reponse to inhaled AMP by 80-8%-compared with 86-6% when the same dose of terfenadine was studied in atopic asthmatic subjects.'2 Since terfenadine and its metabolites are competitive antagonists for histamine at its H, receptors, it is possible that the reduction in FEV, with AMP challenge that remained after treatment with terfenadine 180 mg was due to incomplete antagonism of endogenously released histamine. No further inhibitory activity against inhaled AMP, however, was observed after we increased the dose of Effect oforal terfenadine on the bronchoconstrictor response in non-atopic asthma terfenadine to 600 mg, suggesting that the terfenadine resistant response represents a non-histamine component. The mean time to maximum bronchoconstriction with AMP was delayed from 3-7 minutes after placebo to 16-6 minutes after the higher dose of terfenadine, suggesting that inhaled AMP might also enhance the release of newly formed bronchoconstrictor mediators such as prostaglandin D2 and leukotriene C4, since their release from activated mast cells is delayed beyond that of histamine.2223
The higher dose of terfenadine resulted in less inhibition of the bronchoconstrictor response to inhaled AMP (60 6%) than did terfenadine 180 mg (80 8%), although this difference was not significant. It is difficult to account for this observation. Compliance is unlikely to have been a problem since the two subjects with the greatest bronchoconstrictor response after terfenadine 600 mg showed complete inhibition of the skin weal response to prick testing with histamine at a concentration of 416 mmol/l.
In conclusion, the data presented here are consistent with the suggestion that most of the bronchoconstrictor response to inhalation of AMP in non-atopic asthmatic subjects is due to histamine release in the airways. We suggest that adenosine and its nucleotide AMP cause bronchoconstriction in these non-atopic subjects by potentiating ongoing release of preformed mediators from activated airway mast cells. Our data would also be consistent with an additional effect of these purine derivatives, possibly augmentation of the release of newly generated mediators, either from mast cells or from other mediator secreting cells in the airways.
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